Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Enterprise Therapeutics Ltd. (United Kingdom)
Homepage:
enterprisetherapeutics.com
Alternate names:
Enterprise Therapeutics,
Enterprise Therapeutics Ltd.
ROR:
023en2f83
OpenAlex ID:
I4405267302
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials
2023
·
Toby M. Maher
, Paul Ford
, et al.
·
JAMA
·
155
TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis
2020
·
Henry L. Danahay
, Sarah Lilley
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
96
Emerging Concepts and Therapies for Mucoobstructive Lung Disease
2018
·
Marcus A. Mall
, Henry Danahay
, et al.
·
Annals of the American Thoracic Society
·
64
Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial
2020
·
Steven M Rowe
, Ieuan Jones
, et al.
·
International Journal of COPD
·
63
PDF
TMEM16A: An Alternative Approach to Restoring Airway Anion Secretion in Cystic Fibrosis?
2020
·
Henry Danahay
, Martin Gosling
·
International Journal of Molecular Sciences
·
40
PDF
Potentiating TMEM16A does not stimulate airway mucus secretion or bronchial and pulmonary arterial smooth muscle contraction
2020
·
Henry Danahay
, Roy Fox
, et al.
·
FASEB BioAdvances
·
36
PDF
Investigation of the Role of Protein Kinase D in Human Rhinovirus Replication
2017
·
Anabel Guedán
, Dawid Swieboda
, et al.
·
Journal of Virology
·
32
PDF
Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)
2020
·
Shamsah Kazani
, David J. Rowlands
, et al.
·
Journal of Cystic Fibrosis
·
28
PDF
Potentiation of the cystic fibrosis transmembrane conductance regulator Cl−channel by ivacaftor is temperature independent
2018
·
Yiting Wang
, Zhiwei Cai
, et al.
·
American Journal of Physiology-Lung Cellular and Molecular Physiology
·
15
Niclosamide does not modulate airway epithelial function through blocking of the calcium activated chloride channel, TMEM16A
2023
·
Henry Danahay
, Sarah Lilley
, et al.
·
Frontiers in Pharmacology
·
13
ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo
2024
·
Henry Danahay
, Clive McCarthy
, et al.
·
Journal of Cystic Fibrosis
·
12
Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis
2024
·
Henry Danahay
, Martin Gosling
, et al.
·
European Journal of Medicinal Chemistry
·
6
Reply to Olschewski et al. : TMEM16A Potentiation: Possible Drawbacks
2020
·
Henry L. Danahay
, David G. Morris
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
6
ETD001: A long-acting inhaled ENaC blocker, is well tolerated in humans
2022
·
P Russell
, K Woodward
, et al.
·
European Respiratory Journal
·
3
ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial
2025
·
Paul Russell
, Kathy Woodward
, et al.
·
Journal of Cystic Fibrosis
·
2
PDF
The Tmem16a chloride channel is required for mucin maturation after secretion from goblet-like cells in the Xenopus tropicalis tadpole skin
2024
·
Eamon Dubaissi
, Emma N. Hilton
, et al.
·
Scientific Reports
·
2
Validation of TMEM16A Modulation as a Therapeutic Approach for the Treatment of Cystic Fibrosis: The Discovery of Novel TMEM16A Potentiators
2024
·
Henry Danahay
, Martin Gosling
·
Springer eBooks
·
1
Poster: 107A randomized 28-day, double-blind cross-over study to evaluate the safety, efficacy & pharmacokinetics of ETD001, an inhaled ENaC blocker, in people with cystic fibrosis
2026
·
M. Mall
, S. Sutharsan
, et al.
·
Journal of Cystic Fibrosis
Calcium activated chloride channel (CaCC) in GtoPdb v.2025.4
2025
·
Henry Danahay
, Martin Gosling
, et al.
·
IUPHAR/BPS Guide to Pharmacology CITE
PDF
Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects
2025
·
Paul Miller
, Daniel Repplinger
, et al.
·
Therapeutic Advances in Respiratory Disease
Calcium activated chloride channel (CaCC) in GtoPdb v.2025.3
2025
·
Henry Danahay
, Martin Gosling
, et al.
·
IUPHAR/BPS Guide to Pharmacology CITE
PDF
Show more works
View as search
Works count:
21
Citation count:
1,163
Year
Topic
Type
